bioRxivCancer Biology
Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
A. Sahu, J. Sang Lee, G. Zhang, Z. Wang, T. Tian, T. Moll, G. Kasumova, B. Miao, Z. Wei, N. U. Nair, O. Ponomarova, A. Friedman, A. Amzallag, P. Greninger, R. Egan, L. Damon, D. Frederick, L. Jerby-Arnon, A. Wagner, K. Cheng, W. Robinson, S. G. Park, K. Gardner, S. Hannenhalli, S. Gutkind, , E. Ruppin
Abstract
Most patients with advanced cancer eventually acquire resistance to targeted therapies, spurring extensive efforts to identify molecular events mediating therapy resistance. Many of these events involve synthetic rescue (SR) interactions, where the reduction in cancer cell viability caused by targeted gene inactivation is rescued by an adaptive alteration of another gene (the rescuer). Here we perform a genome-wide prediction of SR rescuer genes by analyzing tumor transcriptomics and survival data of 10,000 TCGA cancer patients. Predicted SR interactions are validated in new experimental screens. We show that SR interactions can successfully predict cancer patients response and emerging resistance. Inhibiting predicted rescuer genes sensitizes resistant cancer cells to therapies synergistically, providing initial leads for developing combinatorial approaches to overcome resistance proactively. Finally, we show that the SR analysis of melanoma patients successfully identifies known mediators of resistance to immunotherapy and predicts novel rescuers.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Predicting resistance to synthetic lethal therapies in cancer
Metin Yazar, Christopher J. Lord, Colm J. Ryan·bioRxiv·Oct 14, 2026
- The immunogenic potential of recurrent cancer drug resistance mutations: an in silico study
Marco Punta, Victoria A. Jennings, … Stefano Lise·Frontiers in ImmunologyPeer-reviewed·Oct 8, 2020
- Whole exome precision oncology targeting synthetic lethal vulnerabilities across the tumor transcriptome
J. S. Lee, N. U. Nair, … E. Ruppin·bioRxiv·Feb 16, 2020
- A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination prediction
Michael P. Menden, Dennis Y.Q. Wang, … Denis Fourches·Nature CommunicationsPeer-reviewed·Jun 17, 2019
- Gene expression based inference of drug resistance in cancer
S. Chawla, A. Rockstroh, … D. Sengupta·bioRxiv·Nov 17, 2021
- Sensitive detection of synthetic response to cancer immunotherapy driven by gene paralog pairs
Chuanpeng Dong, Feifei Zhang, … Sidi Chen·PatternsPeer-reviewed·Feb 25, 2025